If you ask a psychiatrist what causes schizophrenia, the answer almost always includes the word dopamine. The dopamine hypothesis is the oldest and most influential biological model of the condition, and it underwrites the design of every antipsychotic medication on the market. Seventy years after it was first proposed, it is also one of the most extensively revised theories in psychiatry — and even its strongest supporters now treat it as one piece of a larger picture.
Schizophrenia involves a dysregulation of dopamine signalling — too much in some brain regions, possibly too little in others — but dopamine alone does not explain the full disorder.
How it started: the chlorpromazine accident
The story begins in the early 1950s in a Paris hospital, when the French surgeon Henri Laborit noticed that a new compound called chlorpromazine produced an unusual calmness in surgical patients. Psychiatrists Jean Delay and Pierre Deniker tested it in people with severe psychosis and saw something remarkable: hallucinations and delusions softened. It was the first medication that genuinely altered the course of psychotic illness, and its discovery effectively launched modern psychopharmacology.
What no one knew at the time was how chlorpromazine worked. That answer arrived in 1963, when the Swedish pharmacologist Arvid Carlsson — later a Nobel laureate — showed that antipsychotics increased the turnover of dopamine in the brain, suggesting they blocked dopamine receptors. Within a decade, multiple labs confirmed that the clinical potency of antipsychotic drugs correlated remarkably tightly with their ability to bind the dopamine D2 receptor. The dopamine hypothesis was born.
Version 1: "too much dopamine"
The original formulation was simple. Schizophrenia, the theory said, is caused by hyperactive dopamine neurotransmission. Three lines of evidence supported it:
- Antipsychotics block dopamine D2 receptors and reduce psychotic symptoms.
- Drugs that increase dopamine — amphetamines, cocaine, L-DOPA — can produce psychotic-like symptoms in people who do not have schizophrenia, and worsen them in people who do.
- Postmortem studies sometimes showed elevated D2 receptor density in the striatum of people with schizophrenia.
It was a tidy, testable model. It was also wrong in important ways.
The cracks appear
By the 1980s, several findings did not fit the simple "too much dopamine" story. Antipsychotics blocked D2 receptors within hours, but clinical improvement took weeks. Roughly a third of patients did not respond to D2 blockade at all. Negative symptoms (apathy, flat affect, social withdrawal) and cognitive symptoms barely budged. And clozapine — the most effective antipsychotic ever discovered — turned out to have weaker D2 binding than many less effective drugs.
The hypothesis needed an upgrade.
Version 2: regional dysregulation
In the 1990s, a more sophisticated version emerged, often associated with researchers like Kenneth Davis. It proposed that schizophrenia involves too much dopamine in subcortical regions (especially the mesolimbic pathway, driving positive symptoms) and too little dopamine in cortical regions (especially the prefrontal cortex, contributing to negative and cognitive symptoms).
This regional model fit the clinical picture much better. It explained why blunt D2 blockade improved positive symptoms but did little for negative ones, and why amphetamines could worsen paranoia even in people whose prefrontal dopamine was already low.
Version 3: presynaptic dopamine and aberrant salience
The next major revision came from imaging. Beginning in the late 1990s, PET studies — many led by Anissa Abi-Dargham at Columbia and later by Oliver Howes in London — showed that the most consistent finding in schizophrenia is not elevated D2 receptors but elevated dopamine synthesis and release in the striatum. The problem, on this view, is upstream: too much dopamine is being made and released, especially in the associative striatum.
The British psychiatrist Shitij Kapur reframed what this meant clinically. In a widely cited 2003 paper in the American Journal of Psychiatry, he proposed that excess striatal dopamine produces aberrant salience: the brain begins to flag random thoughts, perceptions, and coincidences as urgently meaningful. Delusions, on this view, are the mind's attempt to explain those misplaced signals. A neighbour's glance feels charged with significance, so a story is constructed to make sense of it.
Aberrant salience offered the first coherent bridge between the molecular finding (too much striatal dopamine) and the lived experience of psychosis (everything feels weighted with hidden meaning).
What the dopamine hypothesis explains well
- Why antipsychotics reduce hallucinations and delusions
- Why stimulants worsen positive symptoms
- Why amphetamine challenge produces exaggerated dopamine release on PET in people with schizophrenia
- Why the clinical potency of antipsychotics correlates with D2 affinity
- Why some prodromal patients have elevated striatal dopamine before full psychosis appears
What it does not explain
- Negative symptoms, which are largely unaffected by D2 blockade
- Cognitive symptoms (attention, working memory, processing speed)
- Why ~30% of patients do not respond to standard antipsychotics
- Why the disorder typically emerges in late adolescence rather than earlier
- The genetics of schizophrenia, which point much more strongly to glutamate, immune, and synaptic-pruning systems than to dopamine
This is why most modern researchers think of dopamine dysregulation as a final common pathway rather than the original cause. Something upstream — possibly involving glutamate signalling, immune activity, or developmental synaptic pruning — disrupts the circuits that ordinarily keep striatal dopamine in check. The dopamine excess is what we see, not necessarily where the disorder begins.
What this means for treatment
Every approved antipsychotic still works through the dopamine system. The newest exception is xanomeline-trospium (Cobenfy), a muscarinic agonist that does not directly bind dopamine receptors but is thought to modulate dopamine indirectly. Its FDA approval in 2024 marks the first time in seven decades that a non-dopamine mechanism has been approved for schizophrenia — a small but real sign that the field is finally moving beyond the original hypothesis.
Even so, dopamine remains the workhorse. Understanding the hypothesis — including its limits — helps patients and families make sense of why one medication helps some symptoms and not others, why side effects show up where they do, and why the search for genuinely new treatments has been so slow.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.